Tolerability and efficacy of an enteral formula containing partially hydrolyzed guar gum in patients following gastrointestinal surgery: A prospective, multicenter, open-label, randomized controlled study
Clinical Nutrition · 2026
DOI: 10.1016/j.clnu.2025.12.002 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Nutrition, 2026. Verfasst von Ting Han und 19 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Tenth People's Hospital, Tongji University School of Medicine, 200072, Shanghai, China. Hauptthemen laut MEDLINE: Galactans, Mannans, Plant Gums, Enteral Nutrition. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Nestlé.
Abstract (Originalsprache)
BACKGROUND AND AIMS: Malnourished patients, who undergo gastrointestinal (GI) surgery, have a higher risk of postoperative complications, including higher rates of morbidity and mortality. Generally, a low-fiber diet is recommended after GI surgery. This study investigated the tolerance and clinical outcomes of an enteral formula supplemented with partially hydrolyzed guar gum (PHGG)-a soluble, prebiotic dietary fiber known to benefit gastrointestinal health-in Chinese patients following GI surgery, using a standard fiber-free formula as the control.. METHODS: This study enrolled 631 patients requiring enteral nutrition following GI surgery. Participants were subsequently randomized to receive either a fiber-enriched formula containing 15 g/L PHGG (experimental group, n = 313) or a standard fiber-free formula (control group, n = 318) for 5 days. Data on feeding effectiveness, tolerability, and clinical outcomes were subsequently collected. RESULTS: The incidence of diarrhea was 9.6 % (95 % confidence interval [CI]: 6.3 to 12.8) in the experimental group and 10.1 % (95 % CI: 6.8 to 13.4) in the control group, with an absolute difference of -0.5 (95 % CI: -5.1 to 4.2) confirming non-inferiority (P < 0.001). In patients who consumed ≥4500 kcal over 5 days (averaging 900 kcal/day), the experimental group showed significantly improved feeding tolerance, with a reduced prevalence of diarrhea and abdominal distension (10.4 % vs 24.7 %, P = 0.045; 19.4 % vs 38.4 %, P = 0.016). Patients with gastric cancer in the experimental group had significantly less abdominal distension (22.7 % vs 48.8 %; P = 0.014). Regarding weight preservation, the experimental group demonstrated benefits in weight preservation at discharge (%weight change: -1.39 vs -2.33, P = 0.049). Thirty days after surgery, the experimental group had better EQ-5D scores, especially in E4 pain/discomfort and E5 anxiety. CONCLUSIONS: The PHGG-enriched enteral nutrition formulation is well-tolerated and non-inferior to a fiber-free formula among patients following GI surgery. To maximize its benefits on GI tolerance and body weight preservation, a daily intake of 800-900 kcal is suggested, though this warrants further validation. The trial protocol was registered at www.chictr.org.cn (Identifier: ChiCTR2000038429).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Tenth People's Hospital, Tongji University School of Medicine, 200072, Shanghai, China.
- Department of Gastroenterology, West China Hospital, Sichuan University, 610041, Chengdu, China.
- Department of General Surgery, The Second Affiliated Hospital of Harbin Medical University, 150000, Harbin, China.
- Department of General Surgery, Anhui Medical University, The First Affiliated Hospital of Anhui Medical University, 230022, Hefei, China.
- Department of Gastrointestinal Surgery, The First Affiliated Hospital of Guangxi Medical University, 530021, Nanning, China.
- Peking Union Medical College, Peking Union Medical College Hospital, 100730, Beijing, China.
Förderung
- Nestlé
Zitieren
APA
Han, T., Zhuo, J., Wu, X., Chi, Q., Chen, B., Chen, J., Chen, W., Jia, Z., Zhao, R., Zhang, X., Zhang, P., Mao, Y., Xu, X., Gao, Q., Shen, X., Sun, B., Guo, P., Wang, Z., Yang, J., & Qin, H. (2026). Tolerability and efficacy of an enteral formula containing partially hydrolyzed guar gum in patients following gastrointestinal surgery: A prospective, multicenter, open-label, randomized controlled study. Clinical Nutrition. https://doi.org/10.1016/j.clnu.2025.12.002
Vancouver
Han T, Zhuo J, Wu X, Chi Q, Chen B, Chen J, et al. Tolerability and efficacy of an enteral formula containing partially hydrolyzed guar gum in patients following gastrointestinal surgery: A prospective, multicenter, open-label, randomized controlled study. Clinical Nutrition. 2026. doi:10.1016/j.clnu.2025.12.002
BibTeX
@article{Han2026,
author = {Han, Ting and Zhuo, Jialu and Wu, Xiaoting and Chi, Qiang and Chen, Bo and Chen, Junqiang and Chen, Wei and Jia, Zhenyi and Zhao, Rui and Zhang, Xinyu and Zhang, Peng and Mao, Yuantian and Xu, Xuan and Gao, Qi and Shen, Xiaoding and Sun, Boshi and Guo, Peiang and Wang, Zhen and Yang, Jun and Qin, Huanlong},
title = {Tolerability and efficacy of an enteral formula containing partially hydrolyzed guar gum in patients following gastrointestinal surgery: A prospective, multicenter, open-label, randomized controlled study},
journal = {Clinical Nutrition},
year = {2026},
doi = {10.1016/j.clnu.2025.12.002}
}
EUVIMED